Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.415 +0.095 (+1.79%)
Streaming Delayed Price Updated: 2:20 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 43,745,789
Open 5.520
Bid (Size) 5.410 (43)
Ask (Size) 5.420 (114)
Prev. Close 5.320
Today's Range 5.250 - 5.520
52wk Range 3.790 - 12.36
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype? 
Via MarketBeat
Topics Artificial Intelligence

Performance

YTD
-24.9%
-24.9%
1 Month
+12.1%
+12.1%
3 Month
+2.6%
+2.6%
6 Month
-1.7%
-1.7%
1 Year
-19.4%
-19.4%

More News

Read More
4 Healthcare Stocks to Buy Now
Via The Motley Fool
Topics Artificial Intelligence
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
What's Going On With Recursion Pharmaceuticals Stock On Wednesday?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures
Via MarketMinute
Topics Artificial Intelligence Derivatives
AI Revolutionizes Professional Services: A New Era for Doctors, Lawyers, and Consultants
Via MarketMinute
Topics Artificial Intelligence
Nvidia Has Invested in These 6 Companies. Should You Follow Suit?
Via The Motley Fool
Topics Artificial Intelligence
Where Will Recursion Pharmaceuticals Be in 5 Years?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
The Biotech Stock That's Too Risky for Most Investors
Via The Motley Fool
Topics Artificial Intelligence
10 Hidden-Gem AI Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence
Cramer's Friday Watchlist: AI Soars as Consumer Stumbles Amidst Economic Divide
Via MarketMinute
Topics Artificial Intelligence Economy Energy
Jim Cramer Says This Financial Stock Is A 'Total Spec,' Likes Dutch Bros,
Via Benzinga
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
Via The Motley Fool
Topics Artificial Intelligence
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Via MarketMinute
Topics Animal Testing Artificial Intelligence Intellectual Property
Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Topics Artificial Intelligence
What Analysts Are Saying About Recursion Pharmaceuticals Stock
Via Benzinga
When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts
Via The Motley Fool
Topics Artificial Intelligence ETFs Regulatory Compliance
3 AI Stocks Disrupting Trillion-Dollar Industries
Via The Motley Fool
Topics Artificial Intelligence Economy
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Topics Artificial Intelligence
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 5.415
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 10/13/25 02:20 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 912.03M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 912M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.